AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20943454
Drug: PEG‐IFN plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐IFN plus lamivudine combination therapy
Trial: 16114156
Drug: Valsartan 80
RxNorm normalized name: valsartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 80 mg once daily (n=125)
Trial: 16114156
Drug: Perindopril 4
RxNorm normalized name: perindopril 4 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril 4 mg daily (n=125)
Trial: 2325572
Drug: Low-dose calcitriol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose calcitriol (0.25 micrograms twice daily)
Trial: 2325572
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (1,000 mg/d)
Trial: 6997734
Drug: Single intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intramuscular dose of aqueous penicillin G given at birth
Trial: 24866894
Drug: Dexmedetomidine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine infusion (0.6µg/kg/hour)
Trial: 25636764
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy with irradiation to the internal mammary lymph node (IMN) (Arm 2)
Trial: 25636764
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy without irradiation to the internal mammary lymph node (IMN) (Arm 1)
Trial: 24781178
Drug: Tonsilgon N
RxNorm normalized name: N-6022
DrugBank: N-6022 (DB12206)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tonsilgon N (herbal preparation)
Trial: 24781178
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no herbal preparation)
Trial: 15563538
Drug: Celecoxib (COX-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (COX-2 inhibitor)
Trial: 9833917
Drug: Protein solution
RxNorm normalized name: Plasma protein solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein solution
Trial: 8125392
Drug: Parenteral feeding
RxNorm normalized name: SET,FEEDING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral feeding for 15 days
Trial: 2573444
Drug: MK‐912 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK‐912 2.0 mg
Trial: 2573444
Drug: MK‐912 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK‐912 1.0 mg
Trial: 795007
Drug: Doxycycline 200
RxNorm normalized name: doxycycline 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 200 mg i.v. per day
Trial: 795007
Drug: Benzylpenicillin 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzylpenicillin 10 million I.U. 4 times a day and streptomycin 500 mg twice a day
Trial: 15274404
Drug: Cisplatin-gemcitabine (CG)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin-gemcitabine (CG) - gemcitabine 1125 mg/m2 (days 1 and 8) plus cisplatin 80 mg/m2 (day 2) every 3 weeks for a maximum of 5 cycles
Trial: 15274404
Drug: Epirubicin-gemcitabine (EG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin-gemcitabine (EG) - gemcitabine 1125 mg/m2 (days 1 and 8) plus epirubicin 100 mg/m2 (day 1) every 3 weeks for a maximum of 5 cycles
Trial: 11534915
Drug: Tretinoin cream
RxNorm normalized name: Tretinoin Cream
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tretinoin cream 0.02%
Trial: 2791714
Drug: Ceftriaxone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (2 g single pre‐operative dose, continued daily for 5 days in perforated appendicitis)
Trial: 196421
Drug: LUPIDON H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LUPIDON H or LUPIDON G
Trial: 27967281
Drug: 6.4% maltodextrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.4% maltodextrin solution (MAL)
Trial: 27967281
Drug: 7.1% glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.1% glucose solution (GLU)
Trial: 27967281
Drug: Artificially sweetened
RxNorm normalized name: COLOR,ARTIFICIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artificially sweetened solution (PLA)
Trial: 25557776
Drug: Biofeedback training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biofeedback training twice daily for 5 days, concurrent with CPM therapy
Trial: 23158522
Drug: Everolimus 4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 4.5 mg/m² per day (titrated to achieve blood trough concentrations of 5-15 ng/mL)
Trial: 22082247
Drug: Redesigning Daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Redesigning Daily Occupations program
Trial: 19525739
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (CT) - antidepressants and body‐mind‐spirit group psychotherapy
Trial: 19525739
Drug: Monotherapy (MT)
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (MT) - antidepressants only
Trial: 11198056
Drug: Dothiepin 100
RxNorm normalized name: dothiepin
DrugBank: Dosulepin (DB09167)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dothiepin 100 mg
Trial: 12173784
Drug: Fluvoxamine 100
RxNorm normalized name: fluvoxamine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine 100 mg
Trial: 3828485
Drug: Propranolol administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol administered rectally (80 mg)
Trial: 3828485
Drug: Propranolol administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol administered orally (80 mg)
Trial: 3828485
Drug: Propranolol administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol administered intravenously (2.2 mg)
Trial: 31394146
Drug: ARK intervention
RxNorm normalized name: Arkaliox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARK intervention (Antibiotic Review Kit)
Trial: 26486868
Drug: Recombinant tissue-type
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant tissue-type plasminogen activator 0.9 mg/kg
Trial: 26486868
Drug: Blood pressure-lowering
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood pressure-lowering treatment during the first 24 hours
Trial: 14518310
Drug: Intra-arterial chemotherapy
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial chemotherapy with 5-FU (1000 mg/m2 continuously over 5d/28d) and Folinic Acid (200 mg/m2 over 15 minutes 5d/28d)
Trial: 7912249
Drug: 600 mg/day
RxNorm normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/day of ursodeoxycholic acid (Group A: 18 patients)
Trial: 2574656
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment in Crohn's colitis
Trial: 2574656
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment in ileocolitis
Trial: 2574656
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment in ileitis
Trial: 28286287
Drug: Capecitabine-based treatment
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine-based treatment
Trial: 28286287
Drug: Capecitabine in
RxNorm normalized name: Product containing capecitabine in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine in combination with oxaliplatin and bevacizumab
Trial: 26251016
Drug: Filgrastim 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filgrastim 2.5 µg/kg/day for 7 days
Trial: 26251016
Drug: Filgrastim 5
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Filgrastim 5 µg/kg/day for 7 days
Trial: 26251016
Drug: Filgrastim 10
RxNorm normalized name: pegfilgrastim 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filgrastim 10 µg/kg/day for 5 days
Trial: 26251016
Drug: BK0023 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BK0023 (all doses)
Trial: 3168567
Drug: Methylprednisolone 80
RxNorm normalized name: methylPREDNISolone 80 mg/mL injectable suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 80 mg/24 h and aminophylline by continuous infusion (Group A)
Trial: 3168567
Drug: Sustained-release theophylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release theophylline and methylprednisolone 80 mg in two equally divided doses by mouth (Group B)
Trial: 17564002
Drug: Dexamethasone, 4
RxNorm normalized name: Dexamethasone, 4 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone, 4 mg i.v.
Trial: 17564002
Drug: Ondansetron, 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron, 4 mg i.v.
Trial: 11522614
Drug: MEN 11420
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEN 11420 (8 mg intravenously)
Trial: 9632121
Drug: Serum sex
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum sex hormone-binding globulin (SHBG)
Trial: 7829401
Drug: High-dose metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose metoclopramide plus dexamethasone (HDMP+Dx)
Trial: 2142700
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg dexamethasone
Trial: 30535174
Drug: Parent-implemented communication
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent-implemented communication treatment
Trial: 27501654
Drug: Dorzolamide-timolol treatment
RxNorm normalized name: dorzolamide / timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorzolamide-timolol treatment
Trial: 24712047
Drug: 600 mL
RxNorm normalized name: urinary bag 600 mL-10" MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mL liquid test meal consumed three times (breakfast, lunch, dinner)
Trial: 24712047
Drug: 300 mL
RxNorm normalized name: HYQVIA 30 GM / 300 ML Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mL liquid test meal consumed six times (breakfast, snack, lunch, snack, dinner, snack)
Trial: 24712047
Drug: 600 mL
RxNorm normalized name: urinary bag 600 mL-10" MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mL regimen
Trial: 22159169
Drug: Oral azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral azithromycin (1 g)
Trial: 12760313
Drug: Naproxen 1
RxNorm normalized name: naproxen 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 1 g/day
Trial: 30187872
Drug: ethinyl oestradiol/cyproterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ethinyl oestradiol/cyproterone tablets (Group A)
Trial: 30187872
Drug: desogestrel/ethinyl oestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: desogestrel/ethinyl oestradiol tablets (Group B)
Trial: 30187872
Drug: metformin (for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metformin (for women with insulin resistance)
Trial: 24567309
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral supplementation of multivitamins (B-complex, C and E)
Trial: 14606378
Drug: Epidural infusion
RxNorm normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural infusion of 400 micrograms/h of alfentanil with 50 mg/h of lidocaine (group T-AL)
Trial: 14606378
Drug: Epidural infusion
RxNorm normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural infusion of 400 micrograms/h of alfentanil (group T-A)
Trial: 14606378
Drug: Epidural infusion
RxNorm normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural infusion of 400 micrograms/h of alfentanil (group L-A)
Trial: 2675854
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release oral salbutamol (8 mg)
Trial: 26253869
Drug: S‐1 (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S‐1 (40 mg/m² twice per day) for 2 consecutive weeks repeated every 3 weeks for 1 year
Trial: 26253869
Drug: Cisplatin (CDDP)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin (CDDP) (60 mg/m²) on day 1 plus oral S‐1 (40 mg/m² twice per day) for 2 consecutive weeks repeated every 3 weeks for four cycles
Trial: 22173149
Drug: Morning administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning administration (8:00 to 10:00 a.m.)
Trial: 22173149
Drug: Afternoon administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Afternoon administration (1:00 to 3:00 p.m.)
Trial: 21381157
Drug: Stepped care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepped care ERP (3 sessions over 6 weeks of low-intensity counseling with ERP bibliotherapy, followed by therapist-administered ERP if needed)
Trial: 21381157
Drug: Standard ERP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard ERP (therapist-administered ERP with no lower-intensity lead-in)
Trial: 8343314
Drug: Aspirin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (150 mg)
Trial: 10838018
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose intravenous administration of ivabradine
Trial: 10838018
Drug: Multiple dose
RxNorm normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dose oral administration of ivabradine every 12 hours
Trial: 9178278
Drug: Glutamine-containing parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutamine-containing parenteral nutrition (PN)
Trial: 9178278
Drug: Control parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control parenteral nutrition (isonitrogenous, isoenergetic)
Trial: 22386043
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (iNO) 5 ppm for up to 28 days
Trial: 15807716
Drug: NFV 625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NFV 625 mg (1250 mg bid)
Trial: 15807716
Drug: NFV 625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NFV 625 mg
Trial: 15807716
Drug: NFV 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NFV 250 mg
Trial: 12364482
Drug: Somatostatin (SRIF-14)
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin (SRIF-14) 2.0 micro g/kg/h i.v. over 120 min
Trial: 12364482
Drug: Cortistatin (CST-14)
RxNorm normalized name: hydrogenated poly(C6-14 olefin; 2 CST)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortistatin (CST-14) 2.0 micro g/kg/h i.v. over 120 min
Trial: 10591454
Drug: Surgical treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment, uvulopalatopharyngoplasty
Trial: 1931746
Drug: 2% Remodent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% Remodent and 0.2% NaF solutions
Trial: 1931746
Drug: 0.2% NaF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% NaF solutions (Control group)
Trial: 31565869
Drug: Sequential group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential group (SEQ) - refrained from exercise during months 0 to 6, then supervised exercise program during months 7 to 12
Trial: 31565869
Drug: Sequential group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential group (SEQ) - weight change between 6 and 18 months
Trial: 26447687
Drug: Combined SPT
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined SPT and pregabalin 300 mg daily
Trial: 22309472
Drug: Exposure‐only therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure‐only therapy (Ex)
Trial: 22309472
Drug: Exposure‐based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure‐based treatment combined with cognitive restructuring (ExCR)
Trial: 17705570
Drug: Quinapril 20
RxNorm normalized name: quinapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril 20 mg/day for 6 weeks
Trial: 11348602
Drug: Quinapril 20
RxNorm normalized name: quinapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril 20 mg/day
Trial: 17705570
Drug: Quinapril 40
RxNorm normalized name: quinapril 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril 40 mg/day
Trial: 17705570
Drug: Quinapril 20
RxNorm normalized name: quinapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril 20 mg/day + HCTZ 12.5 mg/day
Trial: 11552924
Drug: 1-week regimen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1-week regimen with ranitidine bismuth citrate 400 mg b.d. for 7 days
Trial: 11552924
Drug: 2-week regimen
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2-week regimen with ranitidine bismuth citrate 400 mg b.d. for 14 days
Trial: 11552924
Drug: 4-week regimen
RxNorm normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-week regimen with ranitidine bismuth citrate 400 mg b.d. for 28 days
Trial: 3144443
Drug: 0.3 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg.kg‐1 nalbuphine intravenously
Trial: 3144443
Drug: 0.1 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg.kg‐1 nalbuphine
Trial: 3144443
Drug: 0.3 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg.kg‐1 nalbuphine
Trial: 27412799
Drug: Taurine (3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taurine (3 g per day)
Trial: 27412799
Drug: Magnesium (340 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium (340 mg per day)
Trial: 27412799
Drug: Taurine (3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taurine (3% solution) and/or high-Mg diet (600 mg per 100 g)
Trial: 22615543
Drug: Combination ART
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination ART in pregnancy
Trial: 14505263
Drug: GnRH-Agonist induced
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH-Agonist induced reversible ovarian suppression
Trial: 1677266
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg of alprazolam
Trial: 29392283
Drug: Pathogen-reduced platelets
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pathogen-reduced platelets in additive solution
Trial: 29392283
Drug: Platelets in
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelets in additive solution
Trial: 29392283
Drug: Pathogen-reduced platelets
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pathogen-reduced platelets in additive solution vs platelets in plasma
Trial: 29392283
Drug: Pathogen-reduced platelets
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pathogen-reduced platelets in additive solution vs platelets in additive solution
Trial: 26712560
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg ranibizumab monthly for 6 months
Trial: 26712560
Drug: 2.0 mg
RxNorm normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg ranibizumab monthly for 6 months
Trial: 19284121
Drug: Succinylcholine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine (1 mg/kg of ideal weight)
Trial: 19284121
Drug: Succinylcholine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine (1 mg/kg of real weight)
Trial: 19284121
Drug: Rocuronium (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium (0.6 mg/kg of ideal weight)
Trial: 19284121
Drug: Rocuronium (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium (0.6 mg/kg of real weight)
Trial: 17873530
Drug: Albendazole (as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole (as preoperative adjuvant therapy)
Trial: 17873530
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy with albendazole and PAIR
Trial: 15692217
Drug: Iron saccharate
RxNorm normalized name: Iron saccharate
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron saccharate complex (ISC), 100 mg twice weekly for 2 months and once weekly thereafter
Trial: 15692217
Drug: Sodium ferric
RxNorm normalized name: Sodium ferric EDTA
DrugBank: Sodium feredetate (DB13381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium ferric gluconate complex (SFGC), 62.5 mg twice weekly for 2 months and once weekly thereafter
Trial: 12667322
Drug: Pituitrin infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pituitrin infusion (2 U/min) during gastroduodenal artery blockage